[go: up one dir, main page]

PT4426307T - New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases - Google Patents

New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases

Info

Publication number
PT4426307T
PT4426307T PT228352498T PT22835249T PT4426307T PT 4426307 T PT4426307 T PT 4426307T PT 228352498 T PT228352498 T PT 228352498T PT 22835249 T PT22835249 T PT 22835249T PT 4426307 T PT4426307 T PT 4426307T
Authority
PT
Portugal
Prior art keywords
therapy
pharmaceutical composition
oral pharmaceutical
interstitial lung
lung diseases
Prior art date
Application number
PT228352498T
Other languages
Portuguese (pt)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PT4426307T publication Critical patent/PT4426307T/en

Links

PT228352498T 2022-06-08 2022-12-08 New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases PT4426307T (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22177750 2022-06-08

Publications (1)

Publication Number Publication Date
PT4426307T true PT4426307T (en) 2025-09-17

Family

ID=81984836

Family Applications (1)

Application Number Title Priority Date Filing Date
PT228352498T PT4426307T (en) 2022-06-08 2022-12-08 New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases

Country Status (1)

Country Link
PT (1) PT4426307T (en)

Similar Documents

Publication Publication Date Title
AU2022407131B2 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
JP2014521658A5 (en)
IL216468B (en) Pharmaceutical compounds for administration by metered dose inhaler containing glycopyrrolate and formoterol and used for the treatment of respiratory diseases
RU2010121827A (en) COMPOSITIONS FOR TREATING PARKINSON'S DISEASE
EA200802012A1 (en) PHARMACEUTICAL PREPARATIONS IN THE FORM OF SOLUTION FOR DOSING INHALERS UNDER PRESSURE
JP2014515373A5 (en)
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
BR112014027010A2 (en) use of high dose laquinimod for treatment of multiple sclerosis
PH12021550218A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
GT200500003A (en) PHARMACEUTICAL COMPOSITION SUITABLE FOR DIRECT COMPRESSION FOR ORAL ADMINISTRATION OF CCI-779
WO2012040228A3 (en) Aerosol composition for administering drugs
IL312742A (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
IL164564A0 (en) Combination therapy for the treatment of cancer
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
PT4426307T (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
HK40115216A (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
MX2018005298A (en) Dosage regimen for a phosphatidylinositol 3-kinase inhibitor.
BR112014004339A2 (en) oral suspension
CN115381939A (en) Pharmaceutical composition for treating Hodgkin's lymphoma and use thereof
WO2016122288A3 (en) Combined formulation including verbenone derivative and therapeutic agent for reperfusion for preventing or treating cerebrovascular diseases, arteriosclerosis or cardiovascular disease
JP2016504361A5 (en)
CA2531620A1 (en) Cancer combination therapy comprising azd2171 and zd1839
RU2017142589A (en) COMPOSITIONS AND METHODS OF TREATMENT OR PREVENTION OF PULMONARY HYPERTENSION
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
MX2021007324A (en) Oral therapy using 6,8-bis-benzylthio-octanoic acid.